Cancer Mechanisms Quiz: Test Oncology Knowledge

Carcinoma originates from epithelial cells, which line surfaces and cavities of organs such as skin, lungs, and gastrointestinal tract. Since epithelial tissues undergo frequent division, they are more prone to accumulating mutations. Approximately 80–90% of human cancers are carcinomas. This distinguishes them from sarcomas, which arise from connective tissue, and from infectious or neurological diseases, which involve entirely different pathological mechanisms and biological systems.

Sarcomas develop from mesenchymal tissues including bone, cartilage, fat, and muscle. These cancers are less common than carcinomas and represent roughly 1% of adult malignancies. Their connective tissue origin explains differences in spread patterns and treatment response. Unlike autoimmune or infectious diseases, sarcomas result from genetic mutations affecting cell cycle regulation, leading to uncontrolled proliferation within structural support tissues of the body.

Ras is a small GTPase protein that acts as a molecular switch in signal transduction pathways. When bound to GTP, it activates downstream pathways such as MAPK, promoting cell growth and survival. Hydrolysis to GDP inactivates it. Mutations impair GTP hydrolysis, keeping Ras continuously active. This leads to uncontrolled proliferation, making Ras one of the most studied oncogenes in cancer biology and targeted therapeutic research.

Ras mutations are typically point mutations affecting codons 12, 13, or 61. These substitutions reduce intrinsic GTPase activity, preventing conversion of GTP to GDP. As a result, Ras remains constitutively active, continuously stimulating growth signaling pathways. Unlike deletions or duplications, point mutations alter single nucleotides yet produce profound biological consequences by locking the protein in a proliferative signaling state associated with oncogenesis.

Mutated Ras remains in a GTP-bound active conformation because defective GTPase activity prevents hydrolysis of the gamma phosphate. This biochemical defect leads to sustained downstream signaling through MAPK and PI3K pathways. Persistent activation promotes growth, survival, and resistance to apoptosis. The inability to revert to the inactive GDP-bound state is central to its oncogenic potential and tumor progression in multiple cancers.

Ras mutations occur in approximately 25–30% of human tumors, though frequency varies by cancer type. For example, pancreatic cancers exceed 90%, while colorectal and lung cancers show intermediate prevalence. This significant percentage demonstrates Ras as a major oncogenic driver. Its widespread involvement highlights the importance of molecular diagnostics and targeted therapies aimed at inhibiting aberrant signaling pathways activated by mutated Ras proteins.

Cancer fundamentally results from accumulated genetic mutations affecting oncogenes and tumor suppressor genes. These mutations disrupt regulatory mechanisms controlling cell division, DNA repair, and apoptosis. Although infections and hormones can influence risk, they act indirectly by promoting genetic instability. Therefore, cancer is best understood as a genetic disease at the cellular level, driven by molecular alterations that enable uncontrolled growth and survival advantages.

Incidence rate measures the number of new cases occurring within a defined population during a specific time period. It differs from prevalence, which includes existing cases. Incidence allows researchers to assess disease risk and trends. Rates are typically expressed per 100,000 individuals annually. Accurate incidence data guide screening programs, prevention strategies, and resource allocation within public health systems and epidemiological research.

Epidemiological data show that approximately 40% of Canadians will develop cancer during their lifetime. This reflects cumulative risk based on aging population demographics and exposure factors. Lifetime probability calculations incorporate incidence trends across age groups. The statistic emphasizes the importance of screening, prevention, and early detection initiatives aimed at reducing morbidity and improving long-term outcomes in the population.

Metastasis refers to the spread of malignant cells from a primary tumor to distant organs via blood or lymphatic systems. This process involves invasion, intravasation, circulation survival, extravasation, and colonization. Metastasis distinguishes malignant from benign tumors. It significantly complicates treatment because secondary tumors may resist therapy and disrupt vital organ function, making disease management more challenging.

Metastasis strongly correlates with decreased survival because systemic spread reduces treatment effectiveness and increases organ dysfunction risk. Survival statistics decline significantly once cancer reaches distant stages. For example, localized cancers often exceed 90% five-year survival, while metastatic disease may fall below 20%. This dramatic difference highlights why early detection is critical in improving long-term patient outcomes and reducing mortality.

Geographic cancer variation suggests environmental exposures, genetic susceptibility, and behavioral patterns influence cancer development. Migration studies show risk profiles change when populations relocate, supporting environmental contribution theories. Dietary habits, pollution, smoking prevalence, and genetic predispositions collectively shape incidence patterns. Such observations strengthen multifactorial causation models rather than single-factor explanations such as climate or healthcare access alone.

Malignant tumors display high mitotic index, enlarged nuclei, increased nuclear-cytoplasmic ratio, and irregular nuclear shapes. Elevated mitotic activity reflects rapid cell division driven by oncogenic mutations. In contrast, benign tumors maintain organized architecture and lower proliferation rates. These microscopic criteria are essential in pathology for distinguishing aggressive malignancies from noninvasive growths and guiding appropriate therapeutic strategies.

Neoplasia describes irreversible, autonomous cell proliferation that persists without external stimuli. Unlike hyperplasia or hypertrophy, which are adaptive and reversible, neoplastic growth continues independently due to genetic alterations. This uncontrolled division forms tumors that may be benign or malignant. The defining feature is loss of normal growth regulation, often requiring surgical or systemic intervention for effective management.

The seed and soil hypothesis, proposed by Stephen Paget, suggests metastasis depends on compatibility between cancer cells and target organ environments. Tumor cells act as “seeds,” while specific organs provide favorable “soil.” This explains why prostate cancer commonly spreads to bone and breast cancer to liver or lung. The theory emphasizes biological compatibility rather than purely mechanical distribution through circulation.